Meyer WH - Search Results

1

Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy.

Furman WL, Rodman JH, Tonda ME, Luo X, Arnold B, Marina N, Garrison L, Hanna R, Pratt CB, Meyer WH. Furman WL, et al. Among authors: meyer wh. Cancer Chemother Pharmacol. 1998;41(3):229-36. doi: 10.1007/s002800050733. Cancer Chemother Pharmacol. 1998. PMID: 9443640 Clinical Trial.

2

Use of GM-CSF in children after high-dose chemotherapy.

Furman WL, Fairclough D, Cain AM, Arnold BA, Pratt CB, Meyer WH, Crist WM. Furman WL, et al. Among authors: meyer wh. Med Pediatr Oncol Suppl. 1992;2:26-30. doi: 10.1002/mpo.2950200707. Med Pediatr Oncol Suppl. 1992. PMID: 1306884

3

Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis.

Marina NM, Pratt CB, Rao BN, Shema SJ, Meyer WH. Marina NM, et al. Among authors: meyer wh. Cancer. 1992 Dec 1;70(11):2722-7. doi: 10.1002/1097-0142(19921201)70:11<2722::aid-cncr2820701125>3.0.co;2-s. Cancer. 1992. PMID: 1423203

4

Sarcomas (other than Ewing's) of flat bones in children and adolescents. A clinicopathologic study.

Kellie SJ, Pratt CB, Parham DM, Fleming ID, Meyer WH, Rao BN. Kellie SJ, et al. Among authors: meyer wh. Cancer. 1990 Feb 15;65(4):1011-6. doi: 10.1002/1097-0142(19900215)65:4<1011::aid-cncr2820650428>3.0.co;2-#. Cancer. 1990. PMID: 2297650

5

Ifosfamide in pediatric malignant solid tumors.

Pratt CB, Douglass EC, Etcubanas EL, Goren MP, Green AA, Hayes FA, Horowitz ME, Meyer WH, Thompson EI, Wilimas JA. Pratt CB, et al. Among authors: meyer wh. Cancer Chemother Pharmacol. 1989;24 Suppl 1:S24-7. doi: 10.1007/BF00253234. Cancer Chemother Pharmacol. 1989. PMID: 2503257

6

Mesna excretion and ifosfamide nephrotoxicity in children.

Goren MP, Pratt CB, Meyer WH, Wright RK, Dodge RK, Viar MJ. Goren MP, et al. Among authors: meyer wh. Cancer Res. 1989 Dec 15;49(24 Pt 1):7153-7. Cancer Res. 1989. PMID: 2510931

7

Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.

Marina NM, Shema SJ, Bowman LC, Rodman J, Douglass EC, Furman WL, Pappo A, Santana VM, Hudson M, Meyer WH, et al. Marina NM, et al. Among authors: meyer wh. Med Pediatr Oncol. 1994;23(4):328-34. doi: 10.1002/mpo.2950230403. Med Pediatr Oncol. 1994. PMID: 8058003

8

Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors.

Marina NM, Rodman JH, Murry DJ, Shema SJ, Bowman LC, Jones DP, Furman W, Meyer WH, Pratt CB. Marina NM, et al. Among authors: meyer wh. J Natl Cancer Inst. 1994 Apr 6;86(7):544-8. doi: 10.1093/jnci/86.7.544. J Natl Cancer Inst. 1994. PMID: 8133538 Clinical Trial.

9

A phase I study of ifosfamide with Mesna given daily for 3 consecutive days to children with malignant solid tumors.

Pratt CB, Meyer WH, Douglass EC, Bowman L, Wilimas J, Ochs J, Marina N, Avery L, Thompson EI. Pratt CB, et al. Among authors: meyer wh. Cancer. 1993 Jun 1;71(11):3661-5. doi: 10.1002/1097-0142(19930601)71:11<3661::aid-cncr2820711131>3.0.co;2-w. Cancer. 1993. PMID: 8490914 Clinical Trial.

10

Phase I trial of subcutaneous interleukin-1 alpha in children with malignant solid tumors.

Furman WL, Luo X, Fairclough D, Garrison L, Marina N, Pratt CB, Bleyer A, Meyer WH. Furman WL, et al. Among authors: meyer wh. Med Pediatr Oncol. 1997 Jun;28(6):444-50. doi: 10.1002/(sici)1096-911x(199706)28:6<444::aid-mpo10>3.0.co;2-9. Med Pediatr Oncol. 1997. PMID: 9143391 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

211 results

Search Page

Filters